On cross-priming of MHC class I-specific CTL: rule or exception?
about
Spatiotemporal Regulation of Hsp90-Ligand Complex Leads to Immune ActivationImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesMurid herpesvirus-4 exploits dendritic cells to infect B cellsViral sequestration of antigen subverts cross presentation to CD8(+) T cells.Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.Bridging innate and adaptive antitumor immunity targeting glycans.Tumor antigen cross-presentation and the dendritic cell: where it all begins?Immunogenicity of cytopathic and noncytopathic viral vectorsThe dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.Lipids, apoptosis, and cross-presentation: links in the chain of host defense against Mycobacterium tuberculosis.CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells.Targeting plasmid-encoded proteins to the antigen presentation pathways.B lymphocytes as antigen-presenting cell-based genetic vaccines.On 'reactivity' versus 'tolerance'.Lipid based particulate formulations for the delivery of antigen.Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentationMesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patientsEnumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infectionInfectious tolerance and the long-term acceptance of transplanted tissue.The potential role of fowlpox virus in rational vaccine design.Immune regulation and evasion of Mammalian host cell immunity during viral infection.Special regulatory T cell review: The suppression problem!Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell primingThe amino acid sequences flanking an antigenic determinant can strongly affect MHC class I cross-presentation without altering direct presentation.Dendritic cell-based immunotherapy for myeloid leukemias.Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells.How do regulatory T cells work?Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.Designing CD8+ T cell vaccines: it's not rocket science (yet).Inhibition of the type I interferon antiviral response during arenavirus infection.On the Role of Dendritic Cells Versus Other Cells in Inducing Protective CD8+ T Cell Responses.In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.Mining the resource of cross-presentationCytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues.Monocytes, viruses and metaphors: hanging the Trojan horse.Immunology: professional secrets.Y in X priming.On observing and analyzing disease versus signals.
P2860
Q26744078-46D54293-DBC5-4EDA-BF64-ED57BBB57903Q26798402-96770CC0-8BFB-4D20-A20D-8445A6AB0B89Q27348688-E509F746-5DDB-45B9-88B0-1461826DDE8AQ33455511-F5D4D0E7-F21A-4485-8A6C-A9C353561217Q33532640-05AA57C3-875C-4DEA-8931-351B821D96A2Q33960021-E291E0C2-86E3-4D6F-8565-5CBC39241837Q34210664-73DACC38-46B4-4CD7-8467-55EB9CEDB6DCQ34716855-43676313-62E9-4720-B29B-38B51D18EFF0Q34771172-02F727E4-6323-481C-81E2-30C320CA6881Q35089558-E0E3B6E0-63AD-4AE7-B651-406189466221Q35567056-E67F9C50-716A-4949-BF68-9299801F68C8Q35826370-AE3AE3FF-104F-49C3-ACB1-3E57EF97413AQ35826422-172E5ABC-02CD-4870-823A-842F5BA32FFCQ35850625-5DD18570-FD67-4BDF-B482-BCECEC3C26A5Q36062119-C36E3356-46E7-40DF-A3FB-D6D1ADEB9D78Q36373352-5CE58497-61C3-4D8A-BC18-A75991874375Q36399737-9CC081FF-8CD6-4EF0-9176-5F52256D0924Q36540118-43866147-27FE-44C1-993F-5107F14A88AEQ36563558-37752682-8104-49CE-AE14-E47EC61765A2Q36600376-635DC53E-34DB-4451-9A2C-DD0A4AECF820Q36832077-A1514F37-263B-4AEE-A914-6E035A96D3EBQ37043712-1E557DF8-52EE-46C8-8BED-AB6347EBA6D5Q37089414-75A0A6F7-4093-4D1E-8E2A-BC2F6A2C28A1Q37372907-8A88EB62-2EA8-4695-ADD7-4370E7E311BFQ37420778-F1026BBF-50A6-4E9A-B4A1-16BEBDC28F8DQ37585179-638CA872-5379-4653-AE1E-49CFA9C52F84Q37596517-A2FB1DF3-1B54-4A8A-B9AE-87E7AA81C086Q37743908-8D658747-8AD7-45E9-A087-6FDE5F73E542Q37744071-FE4B8909-81A1-44AB-84F1-B6726DA7E0FCQ37945195-7DF97C8C-BBC9-4DC2-BE10-B30363708108Q38191608-2F7A4EC6-3388-4ACD-9D98-C55CBB6C15DDQ39815528-8CBEA2E0-36F5-4220-9CBE-FA8A69359612Q40303777-1665583C-D4BF-4F11-9BF3-C1378C20F5FDQ40618967-18073EFC-72D6-473B-B7CF-DF5BA568FAB0Q41981777-F972F049-E40C-437D-A05D-7A39628C9347Q42753262-3458D178-EA1E-43C0-9473-CB05BA116F7EQ43161863-E817C506-0163-4E73-8AFB-DCC46E3F3A69Q44595777-512BDF3D-3C72-4BDE-A099-9B3796C7CFE0Q44637357-D24834B5-9481-4126-AAFC-2AB2A2E4FFF2Q45143199-8082FA77-DA78-480B-88A0-396685EF051E
P2860
On cross-priming of MHC class I-specific CTL: rule or exception?
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
On cross-priming of MHC class I-specific CTL: rule or exception?
@ast
On cross-priming of MHC class I-specific CTL: rule or exception?
@en
On cross-priming of MHC class I-specific CTL: rule or exception?
@nl
type
label
On cross-priming of MHC class I-specific CTL: rule or exception?
@ast
On cross-priming of MHC class I-specific CTL: rule or exception?
@en
On cross-priming of MHC class I-specific CTL: rule or exception?
@nl
prefLabel
On cross-priming of MHC class I-specific CTL: rule or exception?
@ast
On cross-priming of MHC class I-specific CTL: rule or exception?
@en
On cross-priming of MHC class I-specific CTL: rule or exception?
@nl
P1476
On cross-priming of MHC class I-specific CTL: rule or exception?
@en
P2093
Rolf M Zinkernagel
P304
P356
10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V
P407
P577
2002-09-01T00:00:00Z